cetuximab + vemurafenib

Cetuximab + vemurafenib is an investigational combination therapy consisting of two distinct anticancer agents used together, primarily in the treatment of BRAF V600E-mutated metastatic colorectal cancer. Cetuximab is a chimeric monoclonal antibody that targets and inhibits the epidermal growth factor receptor (EGFR), thereby blocking downstream signaling pathways involved in cell proliferation and survival[6]. Vemurafenib is a small molecule inhibitor that selectively targets mutated BRAF serine/threonine kinase, particularly the V600E mutation, leading to inhibition of MAPK pathway signaling and tumor cell apoptosis[8]. The rationale for combining these agents arises from preclinical evidence showing that EGFR inhibition can overcome compensatory feedback activation triggered by BRAF inhibition alone in colorectal cancer cells. This combination has been studied both as a doublet (cetuximab + vemurafenib) and more commonly as part of triplet regimens with irinotecan for enhanced efficacy in refractory or advanced cases[1][2][7].